RTQ1 Stock Chart & Stats
€0.88
€0.00(0.00%)
At close: 4:00 PM EST
€0.88
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.36 - €1.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€385.96M
Enterprise Value€342.34M
Total Cash (Recent Filing)€16.86M
Total Debt (Recent Filing)€14.92M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Preclinical Differentiation Vs ADCsDurable mechanistic differentiation (substantially higher tumor Cmax and tumor selectivity) suggests the platform can deliver a better therapeutic index versus conventional ADCs. That structural advantage can reduce clinical failure risk, improve partner interest across many solid tumors, and support longer-term commercial upside if translated clinically.
Expanded IP And Dual‑payload PlatformAn expanding IP estate around sustained release and dual‑payload capabilities creates a durable competitive moat. Protecting platform innovations supports out‑licensing, partnering leverage, and multiple independent program opportunities, increasing the firm's long‑term optionality and monetisation pathways beyond single‑asset dependence.
Demonstrated Clinical ExecutionConsistent on‑time trial execution and progress on AVA6000 dosing/RDE show operational capability to run multicenter early‑stage studies. Reliable clinical delivery enhances credibility with partners and investors, shortens program timelines if sustained, and materially improves the company’s ability to secure collaborations and funding long term.
Bears Say
Persistent Cash Burn And LossesOngoing deep operating losses and consistently negative free cash flow are structural constraints: they erode equity, reduce financial flexibility, and force reliance on external capital or partnerships. Over months this limits the company’s ability to advance multiple programs simultaneously and increases execution and dilution risk.
Limited Cash RunwayA runway only into early Q1 2027 without partner income creates a structural timeline pressure: critical trial readouts and pivotal starts may require near‑term financing or deals. This constrains strategic choices, can force suboptimal financing terms, and makes multi‑quarter program continuity conditional on external funding.
Dependence On Partners For Pivotal DevelopmentRequiring a partner before initiating pivotal studies transfers control of timelines and commercialization to third parties. This structurally increases uncertainty around trial starts, prolongs time to market, and ties value realisation to successful partner negotiations and alignment, reducing the firm’s independent upside.
Avacta Group plc News
RTQ1 FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest stock price was €0.36 and its highest was €1.04 in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is €385.96M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 76 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on May 19, 2026. The company reported -€0.059 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.059.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -€0.059 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.051%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in DE:RTQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―